In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

If you have liver cirrhosis or chronic hepatitis B infection, you may qualify to participate in a research study that compares the effectiveness of two liver cancer screening methods. Please contact the study team to get more information. Compensation provided.

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Do you have non small cell lung cancer? Are you currently not on any other treatments for your cancer? If you answered yes, you may be able to take part in a lung cancer medication study.

In this study, we want to see how patients with metastatic non-small cell lung cancer do with two treatments: ivonescimab and chemotherapy. We are comparing these treatments to find out which one helps patients more.

In this study, we want to test a new web application we are creating. The app will help users find important information about digital health resources and how ready a community is to use them.

To conduct a pilot trial to determine feasibility and acceptability of the refined PREVAIL model in at least 50 adults with rheumatoid arthritis.